The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas

Abstract : Hepatocyte growth factor (HGF) and its receptor MET are essential during embryonic development and throughout postnatal life. However, aberrant MET activation, due to overexpression, mutations, or autocrine ligand production, contributes to the development and progression of a variety of human cancers, often being associated with poor clinical outcome and drug resistance. B cell malignancies arise from B cells that are clonally expanded at different stages of differentiation. Despite major therapeutic advances, most mature B cell malignancies remain incurable and biologically-oriented therapeutic strategies are urgently needed. This review addresses the role of the HGF/MET pathway during B cell development and discusses how its aberrant activation contributes to the development of B cell lymphoproliferative disorders, with particular emphasis on multiple myeloma and diffuse large B cell lymphoma. These insights, combined with the recent development of clinical-grade agents targeting the MET pathway, provide the rationale to envision the HGF/MET pathway as a new promising target for the treatment of B cell malignancies.
Type de document :
Article dans une revue
BBA - Reviews on Cancer, Elsevier, 2010, 1806 (2), pp.208-219. 〈10.1016〉
Liste complète des métadonnées

https://hal-ens-lyon.archives-ouvertes.fr/ensl-00817062
Contributeur : Agnès Ganivet <>
Soumis le : mardi 23 avril 2013 - 16:21:16
Dernière modification le : vendredi 13 octobre 2017 - 13:16:02

Identifiants

  • HAL Id : ensl-00817062, version 1
  • DOI : 10.1016

Collections

Citation

Karène Mahtouk, Esther P. M. Tjin, Marcel Spaargaren, Steven T. Pals. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. BBA - Reviews on Cancer, Elsevier, 2010, 1806 (2), pp.208-219. 〈10.1016〉. 〈ensl-00817062〉

Partager

Métriques

Consultations de la notice

35